Accessibility Skip to:
  • Accessibility Policy
  • Main Content
  • Main Menu
  • Contact

  • -A: Font Smaller
  • +A: Font Larger
  • Reset Font
  • High Contrast
  • Low Contrast
  • Reset Contrast
History:
You are here:
  • Grand Challenges Canada
  • >
  • Innovations
  • >
  • 0098-01
  • Français
  • Get to Know Us
    • Who We Are
    • Co-CEOs
    • Governance
    • Accountability
    • The Team
    • Partnerships
    • Career Opportunities
    • Service Opportunities
    • Contact Us
  • Learn What We Do
    • What We Do
    • Global Health
    • Humanitarian
    • Indigenous
    • Transition To Scale
    • Innovative Financing
    • Innovations & Results
    • Annual Report
  • Apply for Funding
    • Funding Opportunities
    • Innovator Resources
    • Gender Equality Portal
  • Get Informed
    • News and Media
    • Blog
    • Publications
    • Subscribe
    • Photos and Videos
Grand Challenges Canada

Bold Ideas with Big Impact®

Browse our Innovations and Results
  • Get to Know Us
    • Who We Are
    • Co-CEOs
    • Governance
    • Accountability
    • The Team
    • Partnerships
    • Career Opportunities
    • Service Opportunities
    • Contact Us
  • Learn What We Do
    • What We Do
    • Global Health
    • Humanitarian
    • Indigenous
    • Transition To Scale
    • Innovative Financing
    • Innovations & Results
    • Annual Report
  • Apply for Funding
    • Funding Opportunities
    • Innovator Resources
    • Gender Equality Portal
  • Get Informed
    • News and Media
    • Blog
    • Publications
    • Subscribe
    • Photos and Videos
  • Accessibility
  • Contact
  • Français

Home » Innovations » 0098-01

Hemostatic Nanoparticles to Control Postpartum Hemorrhaging

FacebookTwitterLinked In

Start Date: 30/09/2012- End Date: 01/04/2014


Project Lead(s): Christian Kastrup

Issue

Ninety-nine percent of all maternal deaths occur in resource-poor settings, with more than 30% of these deaths being attributed to postpartum hemorrhage (PPH) and blood loss.

Morbidity and mortality from PPH can largely be avoided through proper prevention, diagnosis and management. However, many women in resource-scarce settings do not have access to quality, assisted delivery by skilled birth attendants and therefore are at a high risk of PPH.

Delivering coagulants deep into damaged tissue during severe bleeding is challenging due to the outward flow of blood and, as a result, severe hemorrhaging is often fatal because the drugs cannot reach and clot blood at its source.

Solution

The project team aimed to develop an easy-to-use, low-cost technology to prevent blood loss, using FDA-approved substances.

The technology is based on simple, self-propelling particles that travel upstream through blood flow and clot blood at the source of damaged vessels.

Animal testing was coupled with a feasibility study showing that the treatment could be effectively distributed and used in low-income countries.

Outcome

Study results show the potential for this approach to manage PPH.

In two mouse models of severe hemorrhage, self-propelling microparticles consisting of CaCO3 and an organic acid were an effective hemostatic. During hemorrhage, propulsion significantly reduced bleeding time and doubled the likelihood of halting hemorrhage.

In mice with lacerated livers, propulsion significantly reduced blood loss.

This knowledge was disseminated through conferences and was published in the journal Science Advances. A patent has also been published. Since the funding period, the technology has been tested and proven safe and effective in two large animal models of severe hemorrhage.

The next stage of the project would be to use the self-propelling particles to create a formulation that can move against blood flow and accumulate in uterine tissue, to stabilize clots in the microvasculature and prevent further blood loss, thereby improving patient outcomes and reducing the morbidity associated with PPH.

Preclinical and clinical feasibility studies must be completed, which are expected to cost $900,000 to $1,200,000.

Stay in touch with this innovator

  • Organization Website
  • Network Website
  • Innovation Overview
    Program

    Stars in Global Health

    Institution

    University of British Columbia

    Institution Country

    Canada

    Implementation Country

    Kenya, Sierra Leone

    Implementation Region

    Sub-Saharan Africa

    Priority

    Maternal Conditions, Post-Partum Hemorrhage

    Platform

    Drug

Grand Challenges Canada’s programs are primarily undertaken with the financial support of the Government of Canada provided through Global Affairs Canada.

Government of Canada
  • Fluxx Technical Support
  • Privacy Policy
  • Website Legal Terms and Disclaimer
We use cookies on our website to give you the most relevant experience by remembering your preferences and activity on our website. By clicking “Accept All”, you consent to the use of ALL the cookies. However, you may click on "Cookie Settings" to select the cookies applicable to your activity and disable those that do not. Please note that you will not be able to disable all cookies as some are necessary for the functioning of the website.
Cookie SettingsAccept All
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Others
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
SAVE & ACCEPT